Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial

The Lancet

Volumn 388, Issue 10058, 2016, Pages 2355-2365

  Liou, Jyh Ming ^a   Fang, Yu Jen ^a   Chen, Chieh Chang ^a   Bair, Ming Jong ^b,c   Chang, Chi Yang ^d   Lee, Yi Chia ^a   Chen, Mei Jyh ^a   Chen, Chien Chuan ^a   Tseng, Cheng Hao ^d   Hsu, Yao Chun ^d   Lee, Ji Yuh ^a   Yang, Tsung Hua ^a   Luo, Jiing Chyuan ^e   Chang, Chun Chao ^f   Chen, Chi Yi ^g   Chen, Po Yueh ^g   Shun, Chia Tung ^a   Hsu, Wen Feng ^a   Hu, Wen Hao ^a   Chen, Yen Nien ^a   Sheu, Bor Shyang ^h   Lin, Jaw Town ^a,i   Wu, Jeng Yih ^j   El Omar, Emad M ^k   Wu, Ming Shiang ^a   more..

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b MACKAY MEMORIAL HOSPITAL   (Taiwan)

^c MEIHO UNIVERSITY   (Taiwan)

^d E DA HOSPITAL   (Taiwan)

^e NATIONAL YANG MING UNIVERSITY   (Taiwan)

^f TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^g CHIA YI CHRISTIAN HOSPITAL   (Taiwan)

^h NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

ⁱ FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^j KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^k UNIVERSITY OF NEW SOUTH WALES   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; CLARITHROMYCIN; LANSOPRAZOLE; METRONIDAZOLE; TETRACYCLINE; ANTACID AGENT; ANTIINFECTIVE AGENT; ORGANOMETALLIC COMPOUND; PROTON PUMP INHIBITOR; UREA;

ABDOMINAL PAIN; ADULT; ARTICLE; BLOATING; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE ELIMINATION; DIZZINESS; DRUG EFFICACY; ERADICATION THERAPY; ESOPHAGOGASTRODUODENOSCOPY; FEMALE; HEADACHE; HELICOBACTER INFECTION; HISTOLOGY; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAPID UREASE TEST; RASH; SEROLOGY; SIDE EFFECT; TAIWAN; TASTE DISORDER; TREATMENT DURATION; UREA BREATH TEST; VOMITING; BREATH ANALYSIS; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG ADMINISTRATION; DRUG EFFECTS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; METABOLISM; MIDDLE AGED; STATISTICS AND NUMERICAL DATA;

AMOXICILLIN; ANTACIDS; ANTI-BACTERIAL AGENTS; BREATH TESTS; CLARITHROMYCIN; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LANSOPRAZOLE; MALE; METRONIDAZOLE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; PROTON PUMP INHIBITORS; TAIWAN; TETRACYCLINE; UREA;

EID: 84994756793     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)31409-X     Document Type: Article

References (37)

1. 1 Ford, AC, Forman, D, Hunt, RH, Yuan, Y, Moayyedi, P, Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomized controlled trials. BMJ, 348, 2014, g3174.
2. 2 Lee, YC, Chiang, TH, Chou, CK, et al. Association between Helicobacter pylori eradication and gastric cancer incidence: a systematic review and meta-analysis. Gastroenterology 150 (2016), 1113–1124.
3. 3 Lee, YC, Chen, TH, Chiu, HM, et al. The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention. Gut 62 (2013), 676–682.
4. 4 Graham, DY, Fischbach, L, Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 59 (2010), 1143–1153.
5. 5 Liou, JM, Chang, CY, Chen, MJ, et al. The primary resistance of Helicobacter pylori in Taiwan after the national policy to restrict antibiotic consumption and its relation to virulence factors—a nationwide study. PLoS One, 10, 2015, e0124199.
6. 6 Megraud, F, Coenen, S, Versporten, A, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 62 (2013), 34–42.
7. 7 Yuan, Y, Ford, AC, Khan, KJ, et al. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev, 12, 2013 CD008337.
8. 8 Greenberg, ER, Anderson, GL, Morgan, DR, et al. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomized trial. Lancet 378 (2011), 507–514.
9. 9 Malfertheiner, P, Bazzoli, F, Delchier, JC, et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomized, open-label, non-inferiority, phase 3 trial. Lancet 377 (2011), 905–913.
10. 10 Liou, JM, Chen, CC, Chen, MJ, et al. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomized trial. Lancet 381 (2013), 205–213.
11. 11 Liou, JM, Chen, CC, Chang, CY, et al. Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: a randomised trial. Gut, 2015, 10.1136/gutjnl-2015-310142 published online Sept 3.
12. 12 Gatta, L, Vakil, N, Vaira, D, Scarpignato, C, Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ, 347, 2013, f4587.
13. 13 Li, BZ, Threapleton, DE, Wang, JY, et al. Comparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis. BMJ, 351, 2015, h4052.
14. 14 Molina-Infante, J, Romano, M, Fernandez-Bermejo, M, et al. Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance. Gastroenterology 145 (2013), 121–128.
15. 15 Graham, DY, Lee, SY, How to effectively use bismuth quadruple therapy: the good, the bad, and the ugly. Gastroenterol Clin North Am 44 (2015), 537–563.
16. 16 Dore, MP, Lu, H, Graham, DY, Role of bismuth in improving Helicobacter pylori eradication with triple therapy. Gut 65 (2016), 870–888.
17. 17 Gisbert, JP, Calvet, X, Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori. Aliment Pharmacol Ther 34 (2011), 604–617.
18. 18 Malfertheiner, P, Megraud, F, O'morain, C, et al. Management of Helicobacter pylori infection—the Maastricht IV/Florence Consensus Report. Gut 61 (2012), 646–664.
19. 19 Chey, WD, Wong, BC, Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 102 (2007), 1808–1825.
20. 20 Fallone, CA, Chiba, N, van Zanten, SV, et al. The Toronto Consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology 151 (2016), 51–69.
21. 21 Luther, J, Higgins, PD, Schoenfeld, PS, Moayyedi, P, Vakil, N, Chey, WD, Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol 105 (2010), 65–73.
22. 22 Venerito, M, Krieger, T, Ecker, T, Leandro, G, Malfertheiner, P, Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection. Digestion 88 (2013), 33–45.
23. 23 Uygun, A, Kadayifci, A, Safali, M, Ilgan, S, Bagci, S, The efficacy of bismuth containing quadruple therapy as a first-line treatment option for Helicobacter pylori. J Dig Dis 8 (2007), 211–215.
24. 24 Songür, Y, Senol, A, Balkarli, A, Basturk, A, Cerci, S, Triple or quadruple tetracycline-based therapies versus standard triple treatment for Helicobacter pylori treatment. Am J Med Sci 338 (2009), 50–53.
25. 25 Liou, JM, Chen, CC, Chen, MJ, et al. Empirical modified sequential therapy containing levofloxacin and high-dose esomeprazole in second-line therapy for Helicobacter pylori infection: a multicentre clinical trial. J Antimicrob Chemother 66 (2011), 1847–1852.
26. 26 Liou, JM, Chang, CY, Sheng, WH, et al. Genotypic resistance in Helicobacter pylori strains correlates with susceptibility test and treatment outcomes after levofloxacin- and clarithromycin-based therapies. Antimicrob Agents Chemother 55 (2011), 1123–1129.
27. 27 Liou, JM, Chen, CC, Chang, CY, et al. Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: a multicentre clinical trial. J Antimicrob Chemother 68 (2013), 450–456.
28. 28 Kitahara, F, Kobayashi, K, Sato, T, Kojima, Y, Araki, T, Fujino, MA, Accuracy of screening for gastric cancer using serum pepsinogen concentrations. Gut 44 (1999), 693–697.
29. 29 Wu, JY, Liou, JM, Graham, DY, Evidence-based recommendations for successful Helicobacter pylori treatment. Expert Rev Gastroenterol Hepatol 8 (2014), 21–28.
30. 30 Graham, DY, Hp-normogram (normo-graham) for assessing the outcome of H. pylori therapy: effect of resistance, duration, and CYP2C19 genotype. Helicobacter 21 (2016), 85–90.
31. 31 Zhang, W, Chen, Q, Liang, X, Liu, W, Xiao, S, Graham, DY, Lu, H, Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy. Gut 64 (2015), 1715–1720.
32. 32 Graham, DY, Lu, H, Yamaoka, Y, A report card to grade Helicobacter pylori therapy. Helicobacter 12 (2007), 275–278.
33. 33 Molina-Infante, J, Lucendo, AJ, Angueira, T, et al. Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study. Aliment Pharmacol Ther 41 (2015), 581–589.
34. 34 Wu, DC, Hsu, PI, Wu, JY, et al. Sequential and concomitant therapy with 4 drugs are equally effective for eradication of H. pylori infection. Clin Gastroenterol Hepatol 8 (2010), 36–41.
35. 35 Yang, JC, Lin, CJ, Wang, HL, et al. High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection. Clin Gastroenterol Hepatol 13 (2015), 895–905.
36. 36 Georgopoulos, SD, Xirouchakis, E, Martinez-Gonzalez, B, et al. Clinical evaluation of a ten-day regimen with esomeprazole, metronidazole, amoxicillin, and clarithromycin for the eradication of Helicobacter pylori in a high clarithromycin resistance area. Helicobacter 18 (2013), 459–467.
37. 37 Liu, KS, Hung, IF, Seto, WK, et al. Ten day sequential versus 10 day modified bismuth quadruple therapy as empirical firstline and secondline treatment for Helicobacter pylori in Chinese patients: an open label, randomised, crossover trial. Gut 63 (2014), 1410–1415.